MARKET

AIMT

AIMT

Aimmune
NASDAQ

Real-time Quotes | Nasdaq Last Sale

15.95
+0.42
+2.70%
Closed 19:55 07/14 EDT
OPEN
15.40
PREV CLOSE
15.53
HIGH
15.96
LOW
15.18
VOLUME
875.38K
TURNOVER
--
52 WEEK HIGH
37.00
52 WEEK LOW
10.09
MARKET CAP
1.04B
P/E (TTM)
-3.5960
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 12 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average AIMT stock price target is 38.82 with a high estimate of 66.00 and a low estimate of 15.00.

EPS

AIMT News

More
Benzinga's Top Upgrades, Downgrades For July 13, 2020
Upgrades * For Darden Restaurants Inc (NYSE: DRI), JP Morgan upgraded the stock from Neutral to Overweight. Darden Restaurants earned ($1.24) in the fourth quarter, compared to $1.76 in the year-ago quarter. The stock has a 52-week-high of $128.41 and a 52-wee
Benzinga · 1d ago
Aimmune Appoints Narinder Singh as Executive Vice President of Technical Operations
Aimmune Appoints Narinder Singh as Executive Vice President of Technical Operations
Business Wire · 07/06 12:30
Edited Transcript of AIMT.OQ earnings conference call or presentation 11-May-20 8:30pm GMT
Q1 2020 Aimmune Therapeutics Inc Earnings Call
Thomson Reuters StreetEvents · 07/02 18:08
Why DBV Technologies Is Plunging Today
MotleyFool.com · 06/26 04:00
Hedge Funds Are Buying Aimmune Therapeutics Inc (AIMT)
Insider Monkey · 06/23 16:05
Down 40% in 6 Months, Is Aimmune Therapeutics a Buy?
MotleyFool.com · 06/18 04:00
BioCryst Berotralstat PDUFA, And Other News: The Good, Bad And Ugly Of Biopharma
Seeking Alpha - Article · 06/11 18:42
Aimmune says peanut allergy drug shows benefit after 2 years
Reuters · 06/08 16:50

Industry

Biotechnology & Medical Research
+2.63%
Pharmaceuticals & Medical Research
+1.70%

Hot Stocks

Symbol
Price
%Change

About AIMT

Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company's therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services. The Company's lead CODIT product candidate, AR101, is an investigational biologic for the treatment of patients with peanut allergy. The Company has initiated Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE), its Phase III registration trial of AR101. The Company is in the process of evaluating additional delivery forms for AR101 for the maintenance phase.
More

Webull offers kinds of Aimmune Therapeutics Inc stock information, including NASDAQ:AIMT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AIMT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AIMT stock methods without spending real money on the virtual paper trading platform.